CureVac Terminates Covid Vaccine Manufacturing Contract With Wacker Chemie, Celonic -- Update
14 Setembro 2021 - 09:43AM
Dow Jones News
By Olivia Bugault
CureVac NV said Tuesday that it will terminate its mRNA
coronavirus vaccine manufacturing contracts with German chemical
company Wacker Chemie AG and biotech company Celonic as it will
need less European production capacity than previously
anticipated.
German biotech company CureVac trades down 3.7% pre-open at its
main listing in the U.S., while Wacker Chemie German-listed shares
are down 0.6%.
"The decision was made in response to the reduced short-term
peak demand for vaccines following the first wave of the pandemic
vaccination efforts and corresponding changes in the demand of its
first-generation COVID-19 vaccine candidate, CVnCoV, currently
under regulatory review with the European Medicines Agency,"
CureVac said.
Existing production and formulation deals with Rentschler
Biopharma and Novartis AG remain in place despite the production
adjustment, CureVac said.
In a separate release today, Wacker Chemie said the move won't
have a significant impact on the earnings and sales of its
biosolutions division this year. "And it does not change our
medium-term targets for the Biosolutions division either," said Dr.
Susanne Leonhartsberger, head of the unit.
In November last year, Wacker Chemie said it had signed a
contract with CureVac for the production of more than 100 million
doses of the vaccine annually at its site in Amsterdam. Production
was supposed to begin in the first half of 2021.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
September 14, 2021 08:28 ET (12:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024